Animal models for COVID-19

C. Muñoz-Fontela; W.E. Dowling; S.G.P. Funnell; P.-S. Gsell; A.X. Riveros-Balta; R.A. Albrecht; H. Andersen; R.S. Baric; M.W. Carroll; M. Cavaleri; C. Qin; I. Crozier; K. Dallmeier; L. de Waal; E. de Wit; L. Delang; E. Dohm; W.P. Duprex; D. Falzarano; C.L. Finch; M.B. Frieman; B.S. Graham; L.E. Gralinski; K. Guilfoyle; B.L. Haagmans; G.A. Hamilton; A.L. Hartman; S. Herfst; S.J.F. Kaptein; W.B. Klimstra; I. Knezevic; P.R. Krause; J.H. Kuhn; R. Le Grand; M.G. Lewis; W.-C. Liu; P. Maisonnasse; A.K. McElroy; V. Munster; N. Oreshkova; A.L. Rasmussen; J. Rocha-Pereira; B. Rockx; E. Rodríguez; T.F. Rogers; F.J. Salguero; M. Schotsaert; K.J. Stittelaar; A. García-Sastre; J. Segalés

doi:10.1038/s41586-020-2787-6

Animal models for COVID-19

C. Muñoz-Fontela, W.E. Dowling, S.G.P. Funnell, P.-S. Gsell, A.X. Riveros-Balta, R.A. Albrecht, H. Andersen, R.S. Baric, M.W. Carroll, M. Cavaleri, C. Qin, I. Crozier, K. Dallmeier, L. de Waal, E. de Wit, L. Delang, E. Dohm, W.P. Duprex, D. Falzarano, C.L. FinchM.B. Frieman, B.S. Graham, L.E. Gralinski, K. Guilfoyle, B.L. Haagmans, G.A. Hamilton, A.L. Hartman, S. Herfst, S.J.F. Kaptein, W.B. Klimstra, I. Knezevic, P.R. Krause, J.H. Kuhn, R. Le Grand, M.G. Lewis, W.-C. Liu, P. Maisonnasse, A.K. McElroy, V. Munster, N. Oreshkova, A.L. Rasmussen, J. Rocha-Pereira, B. Rockx, E. Rodríguez, T.F. Rogers, F.J. Salguero, M. Schotsaert, K.J. Stittelaar, A. García-Sastre, J. Segalés

Departament de Sanitat i d'Anatomia Animals

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

667 Cites (Scopus)

Resum

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.

Idioma original	Anglès
Número d’article	586
Pàgines (de-a)	509-515
Nombre de pàgines	6
Revista	Nature
DOIs	https://doi.org/10.1038/s41586-020-2787-6
Estat de la publicació	Publicada - 23 de set. 2020

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1038/s41586-020-2787-6

Altres arxius i enllaços

Com citar-ho

Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., Qin, C., Crozier, I., Dallmeier, K., de Waal, L., de Wit, E., Delang, L., Dohm, E., Duprex, W. P., Falzarano, D., ... Segalés, J. (2020). Animal models for COVID-19. Nature, 509-515. Article 586. https://doi.org/10.1038/s41586-020-2787-6

@article{a4066167514845bf813719edae1e7ed5,

title = "Animal models for COVID-19",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.",

author = "C. Mu{\~n}oz-Fontela and W.E. Dowling and S.G.P. Funnell and P.-S. Gsell and A.X. Riveros-Balta and R.A. Albrecht and H. Andersen and R.S. Baric and M.W. Carroll and M. Cavaleri and C. Qin and I. Crozier and K. Dallmeier and \{de Waal\}, L. and \{de Wit\}, E. and L. Delang and E. Dohm and W.P. Duprex and D. Falzarano and C.L. Finch and M.B. Frieman and B.S. Graham and L.E. Gralinski and K. Guilfoyle and B.L. Haagmans and G.A. Hamilton and A.L. Hartman and S. Herfst and S.J.F. Kaptein and W.B. Klimstra and I. Knezevic and P.R. Krause and J.H. Kuhn and \{Le Grand\}, R. and M.G. Lewis and W.-C. Liu and P. Maisonnasse and A.K. McElroy and V. Munster and N. Oreshkova and A.L. Rasmussen and J. Rocha-Pereira and B. Rockx and E. Rodr{\'i}guez and T.F. Rogers and F.J. Salguero and M. Schotsaert and K.J. Stittelaar and A. Garc{\'i}a-Sastre and J. Segal{\'e}s",

year = "2020",

month = sep,

day = "23",

doi = "10.1038/s41586-020-2787-6",

language = "English",

pages = "509--515",

}

Muñoz-Fontela, C, Dowling, WE, Funnell, SGP, Gsell, P-S, Riveros-Balta, AX, Albrecht, RA, Andersen, H, Baric, RS, Carroll, MW, Cavaleri, M, Qin, C, Crozier, I, Dallmeier, K, de Waal, L, de Wit, E, Delang, L, Dohm, E, Duprex, WP, Falzarano, D, Finch, CL, Frieman, MB, Graham, BS, Gralinski, LE, Guilfoyle, K, Haagmans, BL, Hamilton, GA, Hartman, AL, Herfst, S, Kaptein, SJF, Klimstra, WB, Knezevic, I, Krause, PR, Kuhn, JH, Le Grand, R, Lewis, MG, Liu, W-C, Maisonnasse, P, McElroy, AK, Munster, V, Oreshkova, N, Rasmussen, AL, Rocha-Pereira, J, Rockx, B, Rodríguez, E, Rogers, TF, Salguero, FJ, Schotsaert, M, Stittelaar, KJ, García-Sastre, A & Segalés, J 2020, 'Animal models for COVID-19', Nature, pàg. 509-515. https://doi.org/10.1038/s41586-020-2787-6

TY - JOUR

T1 - Animal models for COVID-19

AU - Muñoz-Fontela, C.

AU - Dowling, W.E.

AU - Funnell, S.G.P.

AU - Gsell, P.-S.

AU - Riveros-Balta, A.X.

AU - Albrecht, R.A.

AU - Andersen, H.

AU - Baric, R.S.

AU - Carroll, M.W.

AU - Cavaleri, M.

AU - Qin, C.

AU - Crozier, I.

AU - Dallmeier, K.

AU - de Waal, L.

AU - de Wit, E.

AU - Delang, L.

AU - Dohm, E.

AU - Duprex, W.P.

AU - Falzarano, D.

AU - Finch, C.L.

AU - Frieman, M.B.

AU - Graham, B.S.

AU - Gralinski, L.E.

AU - Guilfoyle, K.

AU - Haagmans, B.L.

AU - Hamilton, G.A.

AU - Hartman, A.L.

AU - Herfst, S.

AU - Kaptein, S.J.F.

AU - Klimstra, W.B.

AU - Knezevic, I.

AU - Krause, P.R.

AU - Kuhn, J.H.

AU - Le Grand, R.

AU - Lewis, M.G.

AU - Liu, W.-C.

AU - Maisonnasse, P.

AU - McElroy, A.K.

AU - Munster, V.

AU - Oreshkova, N.

AU - Rasmussen, A.L.

AU - Rocha-Pereira, J.

AU - Rockx, B.

AU - Rodríguez, E.

AU - Rogers, T.F.

AU - Salguero, F.J.

AU - Schotsaert, M.

AU - Stittelaar, K.J.

AU - García-Sastre, A.

AU - Segalés, J.

PY - 2020/9/23

Y1 - 2020/9/23

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85091358247&partnerID=MN8TOARS

UR - https://www.scopus.com/pages/publications/85091358247

U2 - 10.1038/s41586-020-2787-6

DO - 10.1038/s41586-020-2787-6

M3 - Article

SN - 0028-0836

SP - 509

EP - 515

JO - Nature

JF - Nature

M1 - 586

ER -

Animal models for COVID-19

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho